CF
Highly rated in
14
conditions
Highly rated in
14
conditions
Check Dr. Can H. Ficicioglu's experience treating your condition:
About Dr. Can H. Ficicioglu

Can Ficicioglu is a Physiatrist and a Pediatrics expert in Philadelphia, Pennsylvania. Ficicioglu has been practicing medicine for over 37 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Urea Cycle Disorders (UCD), Gaucher Disease, Lysosomal Acid Lipase Deficiency, and Mucopolysaccharidoses (MPS). He is licensed to treat patients in Pennsylvania. Ficicioglu is currently accepting new patients.

His clinical research consists of co-authoring 100 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Can H. Ficicioglu it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Can H. Ficicioglu accepts the following insurance:

  •  Ambetter

Call to see if your plan is accepted.
Locations
3401 Civic Center Blvd, Philadelphia, PA 19104
Background & Education
Graduate Institution
Other, 1985
Specialties
Physiatry
Pediatrics
Licenses
Clinical Genetics in PA
Hospital Affiliations
Childrens Hospital Of Philadelphia
Monmouth Medical Center Southern Campus
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Noninvasive Biomarkers of Hepatic Fibrosis in Urea Cycle Disorders
A Phase 3 Open-Label Extension Study of PTC923 in Phenylketonuria
Longitudinal Study of Urea Cycle Disorders
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
MPS VI Clinical Surveillance Program (CSP)
A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)
Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
A Pilot Study of FDG PET Findings in Patients With Phenylketonuria Before and After BH4 Supplementation
View 10 Less Clinical Trials -

100 Total Publications

Addition of MPS-II to the Recommended Uniform Screening Panel in the United States.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors